Lymphoma
Monoclonal Antibody Therapy before STM for Relapsed or Refractory Lymphoid Malignancies (FH 2361)
A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoid Malignancies; Status: Recruiting; Study ID: NCT01678443
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma. The "RELEVANCE" Trial (Rituximab Lenalidomide Versus Any Chemotherapy)
Investigator: Edward N. Libby, MD; Conditions: Follicular Lymphoma; Status: Recruiting; Study ID: NCT01476787
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigator: Andrei R. Shustov, MD; Conditions: T-Cell Lymphoma; Status: Recruiting; Study ID: NCT01482962
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Investigator: Ajay Gopal, MD ; Conditions: Lymphoma; Status: Closed; Study ID: NCT00947856
A Pilot Study of Weekly Brentuximab Vedotin in Patients With CD30+ Malignancies Refractory to Every >= 3 Week Brentuximab Vedotin
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01703949
A Phase II Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Investigator: Ajay Gopal, MD ; Conditions: Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Marginal Zone B-Cell Lymphoma; Status: Recruiting; Study ID: NCT01282424
A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay Gopal, MD; Conditions: Lymphoma; Status: Open; Study ID: NCT00860171
Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Investigator: David Maloney, MD, PhD; Conditions: Follicular Lymphoma; Status: Recruiting; Study ID: NCT01200589
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Investigator: Andrei R. Shustov, MD; Conditions: Diffuse Large B-Cell Lymphoma; Status: Pending; Study ID: NCT01499303
A Phase 1b, Single-Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Pending; Study ID: NCT01644253
A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With Systemic Anaplastic Large Cell Lymphoma
Investigator: Andrei Shustov, M.D.; Conditions: Anaplastic Large-Cell Lymphoma; Status: Recruiting; Study ID: NCT01309789
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01165112
A Phase II Study of Bendamustine (B), Dexamethasone (D), and GCSF (G) for Peripheral Blood Hematopoietic Stem Cell Mobilization
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma, Multiple Myeloma; Status: Recruiting; Study ID: NCT01110135
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Investigator: Vivian Oehler, M.D,; Conditions: Hematologic Malignancies; Status: Closed; Study ID: NCT00953758
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Investigator: Laura Chow, MD; Conditions: Tumors Characterized by Genetic Abnormalities of ALK; Status: Recruiting; Study ID: NCT01283516
A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma
Investigator: John Thompson, MD ; Conditions: Renal Cell Carcinoma, Non-Hodgkin Lymphoma; Status: Closed; Study ID: NCT01015911
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Investigator: Andrei R. Shustov, MD; Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma; Status: Pending; Study ID: NCT01336933
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Investigator: Ajay K. Gopal, MD; Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma; Status: Pending; Study ID: NCT01510184
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor
Investigator: Leona Holmberg, MD, PhD; Conditions: Non-Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01097057
A Phase 1b/2 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Investigator: Ajay K. Gopal, MD; Conditions: Relapsed Indolent B-cell Lymphoma; Status: Closed; Study ID: NCT01317901
A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy
Investigator: Andrei Shustov, MD; Conditions: Cutaneous T-cell Non-Hodgkin Lymphoma; Status: Recruiting; Study ID: NCT00958074
An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + GA101, a monoclonal anti-CD20 antibody (also known as obinutuzumab or RO5072759), in patients with rituximab-refractory, indolent non-Hodgkin's lymphoma
Investigator: Oliver Press, MD, PhD; Conditions: Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01059630
Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor
Investigator: David Maloney, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia; Status: Recruiting; Study ID: NCT01865617
A Treatment-Option Study of Brentuximab Vedotin (SGN-35) in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Investigator: Andrei Shustov, MD; Conditions: Hodgkin's LymphomaAnaplastic Large-Cell Lymphoma; Status: Closed; Study ID: NCT01196208
A Phase I, Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
Investigator: Andrei Shustov, MD; Conditions: Cutaneous T-Cell Lymphoma; Status: Closed; Study ID: NCT00554827
Phase II Trial Of Response-Adapted Chemotherapy Based On Positron Emission Tomography For Non-Bulky Stage I And II Hodgkin Lymphoma
Investigator: Fred Appelbaum, MD; Conditions: Hodgkin's Lymphoma; Status: Closed; Study ID: NCT01132807
Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma
Investigator: Ajay Gopal, MD; Conditions: Mantle Cell Lymphoma; Status: Closed; Study ID: NCT00843050
A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)
Investigator: Andrei Shustov, MD; Conditions: Non-Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01421667
A multicenter, open-label, Phase 2, safety and efficacy study of the Bruton?s Tyrosine Kinase (Btk) inhibitor, PCI 32765, in subjects with relapsed or refractory de novo diffuse large B-cell lymphoma
Investigator: Andrei Shustov, MD; Conditions: Diffuse Large Cell B-lymphoma; Status: Recruiting; Study ID: NCT01325701
A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab
Investigator: Mohamed Sorror, MD, MSc; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphoid Leukemia; Status: Recruiting; Study ID: NCT01419795
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Investigator: Ajay K. Gopal, MD; Conditions: Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01307267
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma
Investigator: Ann Woolfrey, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01193842
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen
Investigator: Leona A. Holmberg, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT00992446
A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Investigator: Pamela S. Becker, MD; Conditions: Waldenstrom Macroglobulinemia; Status: Pending; Study ID: NCT01536067
Join Us On